Eunice L. Kwak

TL;DR: An NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.

TL;DR: The combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant mCRC, and mutational analysis revealed that the patient achieving a complete response and two of three evaluable patients achieving a partial response had PIK3CA mutations.

TL;DR: MET amplification defines a small and aggressive subset of GEC with indications of transient sensitivity to the targeted MET inhibitor crizotinib (PF-02341066), and survival analysis in patients with stages III and IV disease showed substantially shorter median survival in MET/EGFR-amplified groups.

TL;DR: Treating tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor volume in most patients, and the most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema.

TL;DR: Preoperative FOLFIRINOX followed by individualized chemoradiotherapy in borderline resectable pancreatic cancer results in high rates of R0 resection and prolonged median PFS and median OS, supporting ongoing phase 3 trials.